AstraZeneca enters into $232m asthma drug deal with Synairgen
Under the deal, AstraZeneca will pay Synairgen a $7.25m up-front fee and potential development, regulatory and commercial milestones of about $225m. Additionally, AstraZeneca will pay tiered royalties ranging
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.